RET
Blueprint Medicines, Genentech to Discuss With Regulators Gavreto's Activity in RET-Altered Tumors
Updated results from the ARROW trial showed Gavreto's activity in RET fusion-positive solid tumors beyond NSCLC and thyroid cancer.
LUNGevity Aims for Widespread Comprehensive Biomarker Test Access With New Patient-Facing Campaign
Premium
LUNGevity hopes to streamline patient education messaging and reach lung cancer patients in underserved communities who miss out on comprehensive testing.
AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers
The Phase I/II study results suggest Retevmo may benefit patients with any tumor type that has RET fusions and could support a tissue-agnostic indication.
Turning Point Therapeutics Shares Initial Data on RET Inhibitor, Anticipates FDA Meeting
Following the initial results readout, the firm will expand the Phase I/II SWORD-1 trial and decide on a recommended Phase II dose prior to meeting with regulators.
Swiss Firm Helsinn Doses First Patient in Phase I/II Tumor-Agnostic RET Inhibitor Trial
The company is studying TAS0953/HM06 in roughly 200 patients in Japan and the US whose tumors harbor RET gene abnormalities.